Related Experiment Video
Updated: Aug 4, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
Published on: August 23, 2016
Pegylated interferons
1Washington State University, Spokane, WA, USA.
Abstract:
Interferon therapy for chronic hepatitis C is not a cure, but it is able to decrease the viral load and may decrease the risk of complications (e.g., cirrhosis, liver failure, liver cancer). Pegylation of the interferon increases the amount of time the interferon remains in the body by increasing the size of the interferon molecule. Increasing molecule size slows the absorption, prolongs the half-life, and decreases the rate of interferon clearance. Thus the duration of biological activity is increased with pegylated interferon over nonpegylated interferon. The peginterferon alfa products offer an advantage over nonpegylated interferon alfa products because of less frequent administration. Tolerability of the pegylated interferons is comparable to the nonpegylated formulations. Monotherapy with these agents produces a better response in some patients than monotherapy with the nonpegylated formulation. Combination therapy with ribavirin is more effective than monotherapy. Studies comparing peginterferon alfa-2b and peginterferon alfa-2a in the treatment of chronic hepatitis C have not been performed.
More Related Videos
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
08:13Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
Published on: January 20, 2019
Related Concept Videos
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Dipeptidyl Peptidase 4 Inhibitors
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly